Table 2 Distribution of ongoing and Interrupted/stop drugs
From: Attitudes of patients with a rheumatic disease on drug use in the COVID-19 pandemic
Drugs | Ongoing | Interrupted/stop |
|---|---|---|
bDMARD | 148 (73.3%) | 55 (26.7%) |
Anti-TNF | Â | Â |
 Adalimumab | 30 (90.9%) | 3 (9.1%) |
 Certolizumab | 17 (85%) | 3 (15%) |
 Etanercept | 29 (74.3%) | 10 (25.7%) |
 Golimumab | 18 (81.8%) | 4 (18.2%) |
 Infliximab | 13 (56.5%) | 10 (43.5%) |
 Tocilizumab | 11 (47.8%) | 12 (52.2%) |
 Rituximab | 19 (65.5%) | 10 (34.5%) |
 Secukinumab | 3 (60%) | 2 (40%) |
 Abatacept | 3 (100%) | 0 (0%) |
tDMARD | Â | Â |
Tofasitinib | 5 (83.3%) | 1 (16.7%) |
csDMARD | 124 (95.4%) | 6 (4.6%) |
 Methotrexate | 69 (95.8%) | 3 (4.2%) |
 Leflunomide | 40 (100%) | 0 (0%) |
 Sulfasalazine | 15 (100%) | 0 (0%) |
 Hydroxychloroquine | 70 (93.3%) | 5 (6.7%) |
Low-dose glucocorticoids | 84 (95.4%) | 3 (4.6%) |
NSAIDs | 134 (96.4%) | 5 (3.6%) |